We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BioMarin Autoimmune Drug Gets Orphan Status
BioMarin Autoimmune Drug Gets Orphan Status
December 4, 2009
BioMarin Pharmaceutical has received orphan drug designation for its amifampridine phosphate treatment for a rare autoimmune disease called Lambert Eaton
myasthenic syndrome (LEMS).